Profil
John A.
Skolas was promoted to Executive Vice President, Chief Financial Officer, General Counsel and Secretary in July 2004.
Prior to that, he had served as our Senior Vice President, Chief Financial Officer, General Counsel and Secretary since October 2003.
Prior to that, He served as a consultant and acting chief financial officer for early stage biotechnology companies.
From 2000 through 2001, Mr. Skolas was Chief Financial Officer of Valigen, a privately held genomics company.
From 1999 through 2000, He served as Chief Financial Officer of Coelacanth Corporation (now the pharmaceuticals division of Lexicon Genetics).
From 1997 until 1999, He served as Chief Financial Officer and General Counsel of Phytoworks, Inc. From 1988 until 1997, He also served in various executive positions with EMI Group, PLC, including five years as President and General Counsel of its subsidiary EMI Group Inc. His early career included law practice as a partner in Muchin, Muchin, Bendix & Skolas S.C.
and accounting practice as a Tax Specialist for Coopers & Lybrand, CPA.
Mr. Skolas obtained a CPA certificate from the State of Iowa in 1976.
He earned an MBA from Harvard Business School in 1988 and a JD from the University of Wisconsin in 1977.
Anciens postes connus de John A. Skolas
| Sociétés | Poste | Fin |
|---|---|---|
Genaera Corp.
 Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Directeur Financier/CFO | 01/05/2007 |
Formation de John A. Skolas
| Harvard University | Masters Business Admin |
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |